FindTrial
Sign In

Tetracycline to Limit the Innate Immune Response in Acute Respiratory Distress Syndrome

Innate Immunity in Acute Respiratory Distress Syndrome: A Translational Approach to Limit Inflammasome-dependent Lung Inflammation by Tetracycline

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04079426
Enrollment
50
Registered
2019-09-06
Start date
2019-01-04
Completion date
2022-01-31
Last updated
2019-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Respiratory Distress Syndrome, Pneumonia, Sepsis

Keywords

inflammasome, Caspase, NLRP3, Antibiotics, Tetracycline

Brief summary

The acute respiratory distress syndrome (ARDS) is a severe form of respiratory failure with a mortality rate of approximately 40%. Despite advances in its supportive treatment such as lung protective ventilation or restrictive fluid management, no effective pharmacotherapy exists to treat ARDS. Emerging preclinical data indicates that excessive activation of the inflammasome-Caspase 1 pathway plays a key role in the development of ARDS. Tetracycline has anti-inflammatory properties via inhibiting inflammasome-caspase-1 activation. Since not much is known about the activation of the inflammasome in clinical ARDS, the purpose of this study is i) to investigate the the inflammasome-caspase-1 activation in clinical ARDS and ii) inhibit the innate immune response of alveolar leucocytes obtained by tetracycline from patients with ARDS

Interventions

OTHERSampling of Blood and bronchoalveolar lavage

Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.

Sponsors

University of Bonn
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * Informed consent of the patient * Diagnosis of ARDS for \< 48 h

Exclusion criteria

* Age \< 18 years * Missing informed consent * Immune therapy * Autoimmune disease

Design outcomes

Primary

MeasureTime frameDescription
Cytokine Levels in Serum and bronchoalveolar fluid1 weekdetermined by multiplex Assay \[pg/ml\]
Activation Status of immune cells from blood and bronchoalveolar fluid1 weekincubation of immune cells with tetracycline and Determination of cytokines by multiplex assay \[pg/ml\]
Alarmins in Serum and bronchoalveolar fluid1 weekDetermination by western blot, qPCR or flow cytometry

Countries

Germany

Contacts

Primary ContactChristian Bode, Dr
christian.bode@ukbonn.de+49228287

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026